NCT03801902 2025-09-23Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 TrialNational Cancer Institute (NCI)Phase 1 Completed26 enrolled 17 charts